Effectiveness of Injectable Iron in the Management of Severe Iron Deficiency in Children in Ouagadougou
DOI:
https://doi.org/10.6000/1929-4247.2022.11.04.1Keywords:
Anemia, iron deficiency, child, iron, injectable, Burkina FasoAbstract
Background: Iron deficiency anemia affects 90% of children in Burkina Faso. These studies on the effectiveness of injectable iron are rare in low-income countries with high infant and child mortality related to anemia.
Methods: This has been an observational study to assess the effectiveness of injectable iron in children under five years old admitted to the pediatric ward of the Yalgado Ouédraogo University Teaching Hospital (YO-UTH), in 2019, in Ouagadougou, Burkina Faso.
Findings: Thirty-five (35) children with severe iron deficiency anemia (average age 2.5 years), 60 %( n=21) of whom had decompensated anemia and required transfusion, were treated with injectable iron polymaltose hydroxide and followed up for one month. On average, 226.9± 45.5mg of iron were injected over an average treatment duration of three days. The mean hemoglobin count increased from 4.7± 0.95g/dl at baseline to 9.7±1g/dl (an increase of 4.9g/dl) one month later (p<0.001). The mean corpuscular volume increased from 66.7±4.7fl to 81.5±3.7fl (p<0.001), and that of the ferritinemia varied from 0.02±0.005μg/ml to 0.83±0.09μg/ml (an increase of 0.81μg/ml, p<0.001) and the mean sideremia increased from 4.8±2.1μmol/l to 40.4±5.5μmol/l. No side effects were noted.
Conclusion: By avoiding transfusion in most patients, the use of injectable iron in proven and severe iron deficiency anemias could be a solution in case of blood deficit.
References
World Health Organization. Worldwide prevalence of anaemia 1993-2005. Geneva: World Health Organization; 2008; pp. 6-8.
Soares Magalhães RJ, Clements AC. Spatial heterogeneity of haemoglobin concentration in preschool-age children in sub-Saharan Africa. Bull World Health Organ 2011; 89(6): 459-68. https://doi.org/10.2471/BLT.10.083568
Institut National de la Statistique et de la Démographie (INSD). Enquête démographique et de santé à indicateurs multiples (EDSBF-MICS IV) 2010. INSD; 2012; pp. 150-203.
Ministère de la santé. Plan stratégique nutrition 2010-2015. Ministère de la santé du BF; 2009; pp. 5-6.
Berger J, Dillon JC. Stratégies de contrôle de la carence en fer dans les pays en développement. Cahiers santé 2002; (12): 22-3.
Ministère de la santé: centre national de transfusion sanguine. Projet de rapport d’activité 2018. Centre national de transfusion sanguine; 2019; pp. 37-8.
Ministère de l’économie et des finances: Institut national de la statistique et de la démographie. Annuaire statistique 2016. INSD; 2017; pp. 133-4.
Renard D, Favrat B, Livio F, Buclin T. Traitements de fer : preuves de l’efficacité et bonne pratique clinique. Rev Médicale Suisse 2010; (7): 1-9.
Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. Clin J Am Soc Nephrol. févr 2009; 4(2): 386-93. https://doi.org/10.2215/CJN.02840608
Husson MC, Baumelou A. Evaluation thérapeutique sidérotherapie: intérêt du fer par voie parentérale. CNHIM 1998; 23-41.
Thuret I. Diagnostic biologique de la carence martiale chez l’enfant. Arch Pédiatrie. mai 2017; 24(5): 5S6-13. https://doi.org/10.1016/S0929-693X(17)24003-2
Waldvogel S. Marqueurs diagnostiques de la carence en fer : lequel choisir ? Rev Médicale Suisse 2012; 4.
Beaumont C, Girot R. Métabolisme du fer : physiologie et pathologie. EMC - Hématologie 2010; 5(2): 1-16. https://doi.org/10.1016/S1155-1984(10)49948-3
Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia: Diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91(1): 31-8. https://doi.org/10.1002/ajh.24201
Uni-Pharma. HEMAFER inj. Sol. [332(100Fe3+)]mg/2ml AMP. Uni-Pharma; 2008; pp. 5-8.
Stephen BH, Steven RC, Warren SB, Deborah GG, Thomas BN. Designing Clinical Research. 3e éd. Libr of Cong; 2007; pp. 87-90.
Organisation des Nations Unies pour l’alimentation et l’agriculture. La situation mondiale de l’alimentation et de l’agriculture. FAO; 2017; pp. 34-35.
Institut National de la Statistique et de la Démographie. Enquête sur les indicateurs du paludisme(EIPBF) 2017-2018 2018; pp. 45-50.
Surico G, Muggeo P, Muggeo V, Lucarelli A, Martucci T, Daniele R, et al. Parenteral iron supplementation for the treatment of iron deficiency anemia in children. Ann Hematol 2002; 81(3): 154-7. https://doi.org/10.1007/s00277-001-0418-3
Kriplani A, Mahey R, Dash BB, Kulshreshta V, Agarwal N, Bhatla N. Intravenous iron sucrose therapy for moderate to severe anaemia in pregnancy. Indian J Med Res 2013; 138(1): 78-82.
Mantadakis E, Tsouvala E, Xanthopoulou V, Chatzimichael A. Intravenous iron sucrose for children with iron deficiency anemia: a single institution study. World J Pediatr 2016; 12(1): 109-13. https://doi.org/10.1007/s12519-015-0010-x
Hussain S, Ahmad TM, Sabir MUD, Tarar SH. Comparison of efficacy of oral and intramuscular iron supplementation for the treatment of iron deficiency anemia in children. Pak Armed Forces Med J. 28 févr 2015; 65(1): 153-9.
Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56(4): 615-9. https://doi.org/10.1002/pbc.22930
Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347(aug15 1): 4822-4822. https://doi.org/10.1136/bmj.f4822
Uni-Pharma. Résumé des caractéristiques du produit HEMAFER. Uni-Pharma; 2010; pp. 1-4.
Newnham E, Ahmad I, Thornton A, Gibson PR. Safety of iron polymaltose given as a total dose iron infusion. Intern Med J 2006; 36(10): 672-4. https://doi.org/10.1111/j.1445-5994.2006.01156.x
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
